Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Atossa Therapeutics Price Performance
Shares of NASDAQ:ATOS traded down $0.02 during trading on Wednesday, hitting $0.81. 494,721 shares of the company were exchanged, compared to its average volume of 812,307. The firm's 50 day moving average price is $0.71 and its 200-day moving average price is $0.95. The stock has a market capitalization of $104.76 million, a P/E ratio of -3.69 and a beta of 1.01. Atossa Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.81.
Hedge Funds Weigh In On Atossa Therapeutics
A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE boosted its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,475 shares of the company's stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities & Exchange Commission. 12.74% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on ATOS shares. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the stock a "buy" rating in a research note on Monday, April 21st.
Check Out Our Latest Stock Report on Atossa Therapeutics
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Read More
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
